Switch theme
Sign up to access all valuation multiples
Biosergen AB is a clinical stage biotechnology company advancing the treatment of life-threatening fungal infections. Biosergen’ s mission is to develop the drug candidate BSG005 into a superior antifungal therapy with broader efficacy and improved safety over existing treatments. BSG005 potential is to eliminate fungal infections rather than just slowing their growth, reducing the risk of resistance.
2021
2
Last FY Revenue n/a
LTM EBITDA -$2.2M
$8.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biosergen has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$2.2M.
In the most recent fiscal year, Biosergen achieved revenue of n/a and an EBITDA of -$2.0M.
Biosergen expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biosergen valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$2.2M | XXX | -$2.0M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$2.2M | XXX | -$2.0M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$2.2M | XXX | -$2.0M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Biosergen's stock price is SEK 1 (or $0).
Biosergen has current market cap of SEK 127M (or $13.1M), and EV of SEK 82.0M (or $8.5M).
See Biosergen trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.5M | $13.1M | XXX | XXX | XXX | XXX | $-0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Biosergen has market cap of $13.1M and EV of $8.5M.
Biosergen's trades at n/a EV/Revenue multiple, and -4.3x EV/EBITDA.
Equity research analysts estimate Biosergen's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biosergen has a P/E ratio of -6.1x.
See valuation multiples for Biosergen and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $13.1M | XXX | $13.1M | XXX | XXX | XXX |
| EV (current) | $8.5M | XXX | $8.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -3.9x | XXX | -4.3x | XXX | XXX | XXX |
| EV/EBIT | -3.9x | XXX | -4.3x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.1x | XXX | -6.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -8.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBiosergen's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.0M for the same period.
Biosergen's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biosergen's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Biosergen and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biosergen acquired XXX companies to date.
Last acquisition by Biosergen was XXXXXXXX, XXXXX XXXXX XXXXXX . Biosergen acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Biosergen founded? | Biosergen was founded in 2021. |
| Where is Biosergen headquartered? | Biosergen is headquartered in Sweden. |
| How many employees does Biosergen have? | As of today, Biosergen has 2 employees. |
| Is Biosergen publicy listed? | Yes, Biosergen is a public company listed on STO. |
| What is the stock symbol of Biosergen? | Biosergen trades under BIOSGN ticker. |
| When did Biosergen go public? | Biosergen went public in 2021. |
| Who are competitors of Biosergen? | Similar companies to Biosergen include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Biosergen? | Biosergen's current market cap is $13.1M |
| Is Biosergen profitable? | Yes, Biosergen is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Biosergen? | Biosergen's last 12 months EBITDA is -$2.2M. |
| What is the current EV/EBITDA multiple of Biosergen? | Current EBITDA multiple of Biosergen is -3.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
